Stocks TelegraphStocks Telegraph
Stock Ideas

ALLO Financial Statements and Analysis

NASDAQ : ALLO

Allogene Therapeutics, Inc.

$1.62
-0.05-2.99%
At Close 4:00 PM
$1.61
-0.01-0.62%
After-Market 06:55 PM
63.69
BESG ScoreESG Rating

ALLO FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

ALLO Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
revenue0022.00K21.00K43.00K
cost of revenue03.644M3.555M54.661M3.572M
gross profit0-3.644M-3.533M-54.64M-3.529M
gross profit ratio00-160.591-2.602K-82.07
research and development expenses44.713M46.711M48.704M54.661M45.977M
general and administrative expenses16.333M16.087M17.267M17.224M17.041M
selling and marketing expenses00000
selling general and administrative expenses16.333M16.087M17.267M17.224M17.041M
other expenses10.728M85.00K-929.00K-10.348M-4.545M
operating expenses71.774M62.798M65.971M71.885M63.018M
cost and expenses71.774M66.442M69.526M71.885M63.018M
interest income6.705M4.988M5.433M6.265M6.205M
interest expense100.00K0000
depreciation and amortization3.207M3.644M3.555M3.477M3.572M
ebitda-62.986M-62.798M-65.949M-68.452M-59.403M
ebitda ratio00-2.998K-3.26K-1.381K
operating income-71.774M-66.442M-69.504M-71.864M-62.975M
operating income ratio00-3.159K-3.422K-1.465K
total other income expenses net5.481M5.073M4.504M-13.914M-4.545M
income before tax-66.293M-66.358M-65.00M-85.778M-61.315M
income before tax ratio00-2.955K-4.085K-1.426K
income tax expense0-1.003.512M-65.00K-6.205M
net income-66.293M-66.358M-65.00M-85.778M-61.315M
net income ratio00-2.955K-4.085K-1.426K
eps-0.32-0.35-0.38-0.51-0.37
eps diluted-0.32-0.35-0.38-0.51-0.37
weighted average shs out209.189M190.027M169.128M168.336M167.649M
weighted average shs out dil209.189M190.027M169.128M168.336M167.649M
Graph

ALLO Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
cash and cash equivalents
short term investments
cash and short term investments
net receivables
inventory
other current assets
total current assets
property plant equipment net
goodwill
intangible assets
goodwill and intangible assets
long term investments
tax assets
other non current assets
total non current assets
other assets
total assets
account payables
short term debt
tax payables
deferred revenue
other current liabilities
total current liabilities
long term debt
deferred revenue non current
deferred tax liabilities non current
other non current liabilities
total non current liabilities
other liabilities
capital lease obligations
total liabilities
preferred stock
common stock
retained earnings
accumulated other comprehensive income loss
other total stockholders equity
total stockholders equity
total equity
total liabilities and stockholders equity
minority interest
total investments
total debt
net debt
Graph

ALLO Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
deferred income tax00020.166M1.601M
stock based compensation13.387M13.559M11.924M15.233M15.354M
change in working capital21.191M-16.75M-4.441M-3.401M-14.889M
accounts receivables00000
inventory00000
accounts payables-7.227M6.808M-118.00K-302.00K-3.967M
other working capital27.881M-23.558M-4.323M-3.099M-10.922M
other non cash items-15.607M16.356M17.215M75.00K147.00K
net cash provided by operating activities-44.115M-63.588M-55.899M-53.707M-55.53M
investments in property plant and equipment-429.00K0-8.00K-181.00K-12.00K
acquisitions net000034.255M
purchases of investments-190.762M-42.608M-81.131M-68.702M-199.413M
sales maturities of investments115.199M117.221M103.272M136.344M165.158M
other investing activites074.613M22.141M0-34.255M
net cash used for investing activites-75.992M74.613M22.133M67.461M-34.267M
debt repayment00000
common stock issued-106.952M106.323M1.65M03.194M
common stock repurchased679.00K0856.00K00
dividends paid00000
other financing activites106.952M2.28M1.65M01.091M
net cash used provided by financing activities679.00K108.603M1.65M155.00K4.285M
effect of forex changes on cash0000100.866M
net change in cash-109.136M119.628M-42.408M13.909M-85.512M
cash at end of period61.531M170.667M51.039M93.447M79.538M
cash at beginning of period170.667M51.039M93.447M79.538M165.05M
operating cashflow-44.115M-63.588M-55.899M-53.707M-55.53M
capital expenditure-429.00K0-8.00K-181.00K-12.00K
free cash flow-44.544M-63.588M-55.907M-53.888M-55.542M
Graph

Frequently Asked Questions

How did Allogene Therapeutics, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?

A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, ALLO generated $0.00 in revenue last quarter, while its costs came in at $0.00.

Last quarter, how much Gross Profit did Allogene Therapeutics, Inc. report?

A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Allogene Therapeutics, Inc. reported a $0.00 Gross Profit for the quarter ended Sep 30, 2024.

Have ALLO's Total Operating Expenses and Operating Income been favorable recently?

Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. ALLO incurred $71.77M worth of Operating Expenses, while it generated -$71.77M worth of Operating Income.

How much Net Income has ALLO posted recently?

The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Allogene Therapeutics, Inc., the company generated -$66.29M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.

At the end of the last quarter, how much Cash and Equivalents did Allogene Therapeutics, Inc. have?

The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Allogene Therapeutics, Inc. as of the end of the last quarter was -.

What are ALLO's Total Net Receivables for the last quarter?

Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, ALLO had Total Net Receivables of -.

In terms of Total Assets and Current Assets, where did Allogene Therapeutics, Inc. stand at?

An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of ALLO were -, while the Total Assets stand at -.

As of the last quarter, how much Total Debt did Allogene Therapeutics, Inc. have?

The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of ALLO's debt was - at the end of the last quarter.

What were ALLO's Total Liabilities during the last reported quarter?

A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, ALLO reported total liabilities of -.

How much did ALLO's Working Capital change over the last quarter?

Working Capital Change for ALLO was $21.19M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.

ALLO generated how much cash from operating activities?

An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. ALLO generated -$44.12M of Cash from Operating Activities during its recently reported quarter.

What was ALLO's latest reported Net Change in Cash?

An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. ALLO reported a -$109.14M Net Change in Cash in the most recent quarter.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph